Atlas Trials

Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer

Clinical trial NCT06051851 · UNKNOWN

Trial details

NCT number
NCT06051851
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Pancreatic Adenocarcinoma Metastatic
Start date
2023-07-01
Primary completion
2025-07-01
Enrollment
177

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.